< Back to previous page
Researcher
Patrick Verschueren
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Skeletal Biology and Engineering Research Center (Division)
Member
From1 Apr 2013 → 30 Sep 2022
Projects
1 - 10 of 15
- Optimizing care strategies for patients with rheumatoid arthritis: the impact of comorbiditiesFrom1 Feb 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing remission induction in early rheumatoid arthritis: Towards a novel comprehensive treatment strategy to decrease disease impactFrom27 Sep 2024 → TodayFunding: FWO Strategic Basic Research Grant
- Beyond inflammation: addressing disease impact in rheumatoid arthritisFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Mass spectrometry based immunoprofiling in rheumatoid arthritis patientsFrom1 Oct 2021 → 18 Aug 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
- Implementation of a multimodal screening program for interstitial lung disease in rheumatoid arthritis patientsFrom29 Sep 2021 → 17 Nov 2025Funding: FWO Strategic Basic Research Grant
- Development and clinical validation of a multiplexed massspectrometry- based assay to improve diagnosis of Rheumatoid ArthritisFrom1 Jan 2021 → 31 Dec 2022Funding: FWO Applied Biomedical Research (TBM)
- Complementarity determining region-based immunoprofiling of rheumatoid arthritis.From1 Jan 2021 → 31 Dec 2024Funding: FWO research project (including WEAVE projects)
- How can we optimise the treatment with rituximab for patients with Rheumatoid Arthritis in daily clinical practice?From9 Nov 2020 → 31 Oct 2021Funding: Other federal public and semi-governmental institutions
- Towards a more personalized approach of the ambulatory care for RA patients.From30 Sep 2020 → 30 Sep 2024Funding: FWO Strategic Basic Research Grant
- The Future of Early Rheumatoid Arthritis Management: From Disease Control to Patient WellbeingFrom1 Oct 2018 → 31 Oct 2021Funding: FWO fellowships
Publications
1 - 10 of 180
- Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein(2025)Published in: RMD OpenISSN: 2056-5933Issue: 3Volume: 11
- Effectiveness and patient-reported impact of on-flare retreatment in patients with rheumatoid arthritis: insights from retrospective long-term real-world data(2025)Published in: BMC RheumatolISSN: 2520-1026Issue: 1Volume: 9
- A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial(2025)Published in: RHEUMATOLOGYISSN: 1462-0324Issue: 5Volume: 64Pages: 2505 - 2514
- Occupational history questionnaire for job coding and exposure assessment in systemic autoimmune rheumatic diseases(2025)Published in: Rheumatology Advances in PracticeISSN: 2514-1775Issue: 1Volume: 9
- Skin infections caused by Mycobacterium chelonae: Underestimated, especially in immunocompromised patients(2025)Published in: JEADV CLINICAL PRACTICEISSN: 2768-6566Issue: 1Volume: 4Pages: 262 - 268
- Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study(2025)Published in: RMD OpenISSN: 2056-5933Issue: 1Volume: 11
- Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis(2025)Published in: RMD OpenISSN: 2056-5933Issue: 1Volume: 11
- Integrating pretest probability for rheumatoid arthritis with likelihood ratios of RF and ACPA to improve clinical utility of rheumatoid arthritis autoantibody testing(2025)Published in: CLINICA CHIMICA ACTAISSN: 0009-8981Volume: 564
- New WHO ACPA standard enables standardisation among anti-CCP2 assays, but not other ACPA assays using different antigens(2024)Published in: ANNALS OF THE RHEUMATIC DISEASESISSN: 0003-4967Issue: 12Volume: 83Pages: 1793 - 1794
- Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis(2024)Published in: RMD OpenISSN: 2056-5933Issue: 4Volume: 10